Ionis Pharmaceuticals Gets FDA Approval for Treatment for Severe Hypertriglyceridemia
By Kelly Cloonan
The Food and Drug Administration approved a treatment from Ionis Pharmaceuticals to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia.
The FDA said the drug, called Tryngolza, marks the first treatment shown to reduce the risk of acute pancreatitis -- a sudden inflammation of the pancreas that can be serious or life-threatening -- in adults with severe hypertriglyceridemia.
The FDA said the medications it previously approved to lower triglycerides in severe hypertriglyceridemia patients have not had enough cases of acute pancreatitis in their trials to be able to show a reduced risk of the condition.
Severe hypertriglyceridemia is a serious condition defined by triglyceride levels of at least 500 milligrams per deciliter. When patients' triglycerides levels are that high, guidelines recommend lowering them to reduce the risk of acute pancreatitis, the FDA said. Normal triglyceride levels are less than 150 mg/dL.
Standard treatment for severe hypertriglyceridemia includes lifestyle and diet modifications, such as regular exercise, limiting alcohol consumption, and treating obesity, as well as medications.
The FDA cited two trials supporting the efficacy and safety of Tryngolza.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
June 24, 2026 13:56 ET (17:56 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Buy Trading at Big Discounts
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
United States